Sentence examples for disease trial from inspiring English sources

Randomized control studies involving predominantly adults have recently recruited children with vasculitis too; but rare disease trial design is required for paediatric specific trials.

When it starts, this autumn, the Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease trial will include one thousand volunteers from across the country, aged sixty-five to eighty-five, willwill be studied for three years.

One of our small molecules, the p75NTR ligand, LM11A-31, has progressed through a human phase 1 safety trial and is in a phase 2a Alzheimer's disease trial ongoing in Europe.

Then there is the vast REVEAL heart disease trial, which recruited 19,000 Britons in record time.These studies have something in common: researchers were able to trawl NHS data to find appropriate subjects and contact them directly.

In retrospect, after the outcome of the Parkinson's disease trial, it seems almost naïve to count on fragments of fetal tissue that are not standardized with regard to their cellular and molecular contents to grow, mature, migrate and function with the exquisite equipoise of an organ like the brain.

The endoscopic substudy of the ACCENT I (A Crohn's Disease Clinical Trial Evaluating Infliximab in a New Long-term Treatment Regimen) Crohn's disease trial examined the effects of infliximab on mucosal inflammation and mucosal healing, and assessed their impact on outcomes.

Improved design of prodromal Alzheimer's disease trials through cohort enrichment and surrogate endpoints.

Weninger S, Carrillo MC, Dunn B, et al. Collaboration for Alzheimer's Prevention: Principles to Guide Data and Sample Sharing in Preclinical Alzheimer's Disease Trials.

In addition, the monoclonal antibodies, bevacizumab and cetuximab, have been integrated into recent randomized clinical trial designs, based on efficacy data from advanced disease trials.

The day's discussion will center around novel approaches to trial design and analysis to improve efficiency and interpretability of results in rare disease trials.

When high-profile pharma studies fail – such as the slew of recent Phase 3 Alzheimer's Disease trials – it's fashionable to characterize them as yet another industry failure.